Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC - Slideshow
Tenaya Therapeutics, Inc. recently presented data from the RIDGE-1 Phase Ib/II study on their TN-401 gene therapy targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The presentation included a slide deck detailing the findings and implications of the therapy. This event marks a significant step in the development of gene therapies for this specific cardiac condition.
- ▪Tenaya Therapeutics, Inc. discussed data from the RIDGE-1 Phase Ib/II study.
- ▪The focus was on their TN-401 gene therapy for PKP2-associated ARVC.
- ▪A slide deck was published in conjunction with the presentation.
Seeking Alpha files mainly under finance. We currently carry 6,081 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4905876-tenaya-therapeutics-inc-tnya-discusses-ridgeminus-1-phase-ib-ii-data-on-tnminus-401-gene"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
